Related Experiment Video

Updated: Oct 13, 2025

Establishment and Characterization of Patient-Derived Xenograft Models of Anaplastic Thyroid Carcinoma and Head and Neck Squamous Cell Carcinoma
06:08

Establishment and Characterization of Patient-Derived Xenograft Models of Anaplastic Thyroid Carcinoma and Head and Neck Squamous Cell Carcinoma

Published on: June 2, 2023

1.9K

Management of VEGFR-Targeted TKI for Thyroid Cancer

Tomohiro Enokida1, Makoto Tahara1

  • 1Department of Head and Neck Medical Oncology, National Cancer Center Hospital East, 6-5-1 Kashiwanoha, Kashiwa 277-8577, Japan.

Cancers
|November 13, 2021
PubMed

Insights

Multitarget tyrosine kinase inhibitors (MTKIs) improve advanced thyroid cancer treatment but cause adverse events. This review details MTKI side effects, their management, and strategies for safer patient care.

Area of Science:

  • Oncology
  • Pharmacology

Background:

  • Multitarget tyrosine kinase inhibitors (MTKIs) targeting VEGFR have transformed advanced thyroid cancer treatment.
  • Despite improved prognoses, MTKIs cause adverse events that can lead to treatment interruption and reduced quality of life.

Purpose of the Study:

  • To review the mechanisms, characteristics, and management of adverse events associated with MTKIs in advanced thyroid cancer.
  • To discuss factors influencing MTKI safety, including alternative therapies, patient selection, and education.

Main Methods:

  • Literature review summarizing current knowledge on MTKI-related adverse events.
  • Analysis of potential mechanisms and clinical manifestations of side effects.

Main Results:

  • Common adverse events include hypertension, proteinuria, renal impairment, hemorrhage, gastrointestinal issues, cardiovascular toxicities, and fatigue.
  • Effective management strategies exist for these side effects, aiming to maintain treatment continuity and quality of life.

Conclusions:

  • Understanding and managing MTKI adverse events is crucial for optimizing advanced thyroid cancer treatment.
  • Personalized treatment approaches, including careful patient selection and education, are essential for maximizing therapeutic benefits while minimizing risks.
Keywords:
adverse eventthyroid cancertyrosine kinase inhibitorvascular endothelial growth factor

More Related Videos

Computer-Aided Three-Dimensional Visualization in the Treatment of Locally Advanced Thyroid Cancer03:55

Computer-Aided Three-Dimensional Visualization in the Treatment of Locally Advanced Thyroid Cancer

Published on: June 9, 2023

671
In Vivo Inhibition of MicroRNA to Decrease Tumor Growth in Mice07:02

In Vivo Inhibition of MicroRNA to Decrease Tumor Growth in Mice

Published on: August 23, 2019

7.5K

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.9K
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers01:26

Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers

Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
282
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.4K
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists01:18

Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists

Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
246
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
726
Synthesis and Regulation of Thyroid Hormones01:20

Synthesis and Regulation of Thyroid Hormones

Low blood levels of the thyroid hormones — triiodothyronine (T3) and thyroxine (T4) — signal the hypothalamus to release the thyrotropin-releasing hormone (TRH). TRH then reaches the pituitary gland and stimulates the release of thyroid-stimulating hormone(TSH) into the bloodstream.
Upon reaching the thyroid gland, TSH stimulates the follicular cells' active uptake of iodide ions from the blood. The ions diffuse to the apical surface of the cells and are oxidized to iodine. The...
5.5K